CRT-64 Impact of Periprocedural Myocardial Infarction following Chronic Total Occlusion Interventions on mid-term Angiographic and 2-year Clinical Outcomes  by Rha, Seung-Woon et al.
was achieved using medical records and/or phone calls and was censored at 2 years.
Descriptive analysis was performed on all variables. Univariate analysis and propensity
matched analysis were performed to determine differences between the 2 cohorts.
Results: E had more hypertension and a higher angiographic complexity than Y patients
as judged by SYNTAX scoring (E 22.4  14.2; Y 17.5  12.5, p  0.026). A higher
prevalence of smoking, obesity and family history of premature heart disease was seen in
Y patients. At 2 years follow up, Y vs. E patients had the following outcomes respectively:
TLF 27.7% and 25.5% (p0.711), TLR (24.8% vs. 21.4%, p0.518), cardiac death
(3.4% vs. 2.5%, p0.750) and definite and probable stent thrombosis (2.0% vs. 1.0%).
Propensity matched analysis showed a statistically similar TLF and TVF between the Y
and E cohorts respectively (31.3% vs. 21.9% (p0.317) and 46.2% vs. 32.3% (p0.150)
respectively). The EES had lower TLR than PES in the E (15.7% vs. 27.7%, p0.055)
but similar outcomes between the 2 stents were seen in the Y cohort.
Conclusion: In this cohort of patients receiving EES and PES, and when compared to
young patients ( 65 years), elderly patients ( 65 years) had more complex angiographic
disease but statistically similar outcomes at 2- year follow-up. EES appears to have lower
TLR in elderly patients than PES.
CRT-63
Multi Center, Prospective, Randomized, Single Blind, Consecutive Enrollment
Evaluation A Novolimus-eluting Coronary Stent System With Bioabsorbable Polymer
Compared To a Zotarolimus-eluting Coronary Stent System: 12- Month Clinical And
6-month Angiographic and IVUS Results: The Excella BD Study
Alexandre Abizaid,1 Joachim Schofer,2 Roberto Botelho,3 Stefan Verheye,4
Ricardo Costa,5 Luiz Fernando Tanajura,1 Sara Toyloy,6 Lynn Morrison,6
Peter Fitzgerald7
1Instituto Dante Pazzanese, Sao Paulo, Brazil 2Universitäres Herz-und
Gefäzentrum, Hamburg, Germany 3Instituto do Coração do Triângulo Mineiro,
Uberlandia, Brazil 4ZNA Middelhiem, Antwerpen, Belgium 5Cardiovascular Research
Center, Sao Paulo, Brazil 6Elixir Medical Corporation, Sunnyvale, CA; 7Stanford
Cardiovascular Core Analysis Laboratory, Stanford, CA
Background: To evaluate the safety and effectiveness of the Elixir DESyneTM BD
Novolimus Eluting Coronary Stent System (CSS) with a bioabsorbable polymer com-
pared to the Endeavor Zotarolimus Eluting Coronary Stent System through the
assessment of clinical, angiographic, and IVUS endpoints.
Method: 149 patients were randomized 3:1, either to the Elixir DESyne BD Novolimus
Eluting CSS loaded with 5mcg per mm of stent length of Novolimus, a sirolimus
metabolite, eluted via a bioabsorbable polylactide-based polymer, or to the Endeavor
Zotarolimus-eluting CSS loaded with 10mcg per mm of stent length of Zotarolimus
eluted via a durable phosphoryl choline polymer. All patients were analyzed for the
primary endpoint of in-stent late lumen loss (LLL) assessed by QCA at 6 months.
Moreover, all patients underwent evaluation for the secondary endpoints including the
Device-orientated Composite Endpoint (DoCE) defined as: cardiac death, MI not clearly
attributable to a non-intervention vessel, and clinically-indicated target lesion revascular-
ization; clinically-indicated Target Vessel Revascularization (TVR), and stent thrombosis
at 1, 6, 9, and 12 months and annually through 5 years. Lesions were also evaluated for
angiographic endpoints at 6 months including: in-segment LLL, percent diameter
stenosis, minimal lumen diameter post-procedure and at 6 months, and angiographic
binary restenosis (ABR) (50%). A subset of patients underwent intravascular ultrasound
(IVUS) evaluation including percent (%) neointimal obstruction at 6 months.
Results: The study met the primary endpoint demonstrating both non-inferiority and
superiority of the DESyne BD compared to the control (0.120.15 vs 0.670.47,
p0.001), additionally, in-stent ABR was significantly lower for DESyne BD (0% vs
7.9%, p0.003). Excellent clinical results at 6 months were demonstrated for both
devices. Clinical results through 12 months and additional angiographic and IVUS results
will be presented.
Conclusion: Clinical results through 12 months and complete angiographic and IVUS
results will be presented.
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Background: Chronic total occlusion (CTO) intervention is still challenging because of
the limited procedural success rate and higher recurrence. It is not clear whether the
peri-procedural myocardial infarction (P-MI) will significantly impact on angiographic
and clinical outcomes following CTO intervention.
Methods: A total of 131 consecutive pts underwent CTO intervention were divided into
P-MI (n12) and control group (n119). Six-month angiographic and twelve-month
clinical outcomes were compared between the two groups.
Results: The baseline clinical characteristics were balanced between the two groups
except more elderly (66.113.0 vs. 60.19.4 p0.034) in the P-MI group. There were
higher incidence of perforation (15.3% vs. 0.7%, p0.0005), dissection (46.1% vs.18.1%,
p0.018), any hematoma and acute renal failure in the P-MI group. Angiographic
outcomes at 6 months were not different between the two groups. However, the incidence
of total death, any myocardial infarction (MI) and target vessel revascularization
(TVR)-major adverse cardiac events (MACE) were higher in the P-MI group at 24
months (Table).
Conclusions: P-MI following CTO intervention was associated with higher 2-year
mortality, any MI and TVR-MACE. Careful procedure to minimize P-MI will be
warranted to get optimal CTO intervention outcomes.
CRT-65
Multi Center, Prospective, Randomized, Single Blind, Consecutive Enrollment
Evaluation Of The Elixir DESyneTm Novolimus-eluting Coronary Stent System With
Durable Polymer Compared To The Endeavor Zotarolimus-eluting Coronary Stent
System: 3-year Clinical Results And 9-month Angiographic And IVUS Results: The
Excella II Study
Alexandre Abizaid,1 Stefan Verheye,2 Christophe Dubois,3 Karl E. Hauptmann,4
John Ormiston,5 Jim Stewart,5 Joachim Schofer,6 Karl Stangl,7
Bernhard Witzenbichler,8 Marcus Wiemer,9 Emanuele Barbato,10 Peter Fitzgerald,11
Hiromasa Otake,11 Patrick Serruys12
1Instituto Dante Pazzanese, Sao Paulo, Brazil 2ZNA Middelhiem, Antwerpen,
Belgium 3Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium 4Krankenhaus der
Barmherzigen Brueder, Trier, Germany 5Mercy Angiography Unit, Auckland, New
Zealand 6Hamburg University Cardiovascular Center, Hamburg, Germany 7Charité,
Universitätsmedizin Berlin, Berlin, Germany 8Charite Campus Benjamin Franklin,
Berlin, Germany 9Herz-und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen,
Germany 10Onze Lieve Vrouw Ziekenhuis, Aalst, Belgium 11Stanford Cardiovascular
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 2 , S u p p l S , 2 0 1 3 S21
C
O
R
O
N
A
R
Y
